Korsana Biosciences, Inc. (KRSA) vs Veraxa Biotech Holding AG (VRXA)

A side-by-side comparison of Korsana Biosciences, Inc. and Veraxa Biotech Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KRSA

Korsana Biosciences, Inc.

$149M

$31.77HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

VRXA

Veraxa Biotech Holding AG

$153M

$1.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — KRSA vs VRXA

growth of $100 · dividends reinvested · last 1y

KRSA +38.0% (+38.0%/yr)VRXA -90.8% (-90.8%/yr)KRSA compounded faster over this window

Log scale — wide-divergence pair

KRSA VRXA

Metrics side by side

Total return (annualized)

Metric	KRSA	VRXA
Total return (1Y)	75.07%	N/A
Total return CAGR (3Y)	11.57%	N/A
Total return CAGR (5Y)	-40.41%	N/A

VRXA is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full KRSA analysis Full VRXA analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.